Company Filing History:
Years Active: 2011
Title: Angela Pelliccia: Innovator in Monoclonal Antibody Research
Introduction
Angela Pelliccia is a prominent inventor based in Rome, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her innovative work has the potential to impact various medical applications.
Latest Patents
Angela holds a patent for an anti-human tenascin monoclonal antibody. This invention describes an antibody whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively. The antibody's proteolytic fragments are capable of binding to an antigenic epitope within the A-D region of human tenascin. Additionally, it includes its recombinant derivatives, conjugates, and similar functional analogues that can bind to the same antigenic epitope.
Career Highlights
Angela Pelliccia is associated with Tecnogen S.c.p.a., where she has been instrumental in advancing research in her field. Her dedication to innovation has led to the development of groundbreaking technologies that enhance therapeutic options for patients.
Collaborations
Angela has collaborated with notable colleagues, including Rita De Santis and Giovanna Palombo. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.
Conclusion
Angela Pelliccia's contributions to monoclonal antibody research exemplify her commitment to innovation in biotechnology. Her patent on the anti-human tenascin monoclonal antibody showcases her ability to develop solutions that could lead to significant advancements in medical treatments.